SC
CTIC

Steven Cohen’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Steven Cohen’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,757,800
Closed -$10.6M – 2631
2022
Q4 		$10.6M Buy
1,757,800
+1,649,890
+1,529% +$9M 0.04% 530
2022
Q3 		$628K Sell
107,910
-571,933
-84% -$3.56M ﹤0.01% 1130
2022
Q2 		$4.06M Buy
+679,843
New +$3.48M 0.02% 761

Other funds holding CTIC

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Steven Cohen's CTIC Position: Q1 2023 in Review

Steven Cohen sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q1 2023, closing a stake of 1,757,800 shares — an estimated $10.6M sold.

Steven Cohen first reported a position in CTIC in Q2 2022 and held it in 3 quarters. The position peaked at $10.6M in Q4 2022. 133 funds tracked by Wall St. Rank hold CTIC as of Q1 2023.

  • Steven Cohen reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q1 2023 after selling out during the quarter.
  • Steven Cohen sold 1,757,800 CTI BioPharma Corp. (DE) Common Stock shares in Q1 2023, an estimated $10.6M.
  • Steven Cohen first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q2 2022 and held it in 3 quarters.
  • Steven Cohen's CTI BioPharma Corp. (DE) Common Stock position peaked at $10.6M in Q4 2022.
  • 133 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q1 2023.

Based on Point72 Asset Management's 13F filing for Q1 2023, filed 15 May 2023.